Key result
QT-prolonging drug prescriptions affect ~42% of older patients with major neurocognitive disorder, most commonly donepezil.
Why the study?
People with major neurocognitive disorder may be susceptible to drug-induced QT interval prolongation, motivating an investigation into the prevalence of QT-prolonging drugs, drug-drug interactions, and associated factors in this population.
Population
35,212 older people with major neurocognitive disorder in Sweden
Comparison
QT-prolonging drug use vs no use across age and gender
Design
Register-based cross-sectional study
Authors
Loading...
Common QT-prolonging prescriptions may heighten arrhythmia risk in this population; cross-sectional data leaves open whether reviews improve outcomes.
Cross-Sectional (n=35,212)
QT-prolonging drugs and potentially dangerous drug-drug interactions are highly prevalent among older adults with major neurocognitive disorders, highlighting the need for careful medication review to prevent arrhythmias.
Gustafsson et al. (2022) conducted a cross-sectional in Major Neurocognitive Disorder (n=35,212). QT-prolonging drugs was evaluated on Prevalence of one or more prescribed QT-prolonging drugs. Among older people with major neurocognitive disorder, 41.6% were prescribed at least one QT-prolonging drug, with donepezil being the most common (25.0%).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: